Table 1.
Pre-menopausal | Post-menopausal | |||
---|---|---|---|---|
Baseline | 3 months | Baseline | 3 months | |
(n = 18) | (n = 18) | (n = 20) | (n = 19) | |
Age | 48.5 (47.5–49.4) | 53.0 (51.6–54.4) | ||
Body weight (kg) | 66.1 (62.4–69.8) | 66.1 (62.4–69.4) | 67.0 (62.8–71.2) | 66.5 (61.9–71.2) |
BMI | 23.5 (22.4–24.6) | 23.4 (22.4–24.5) | 23.6 (22.5–24.8) | 23.5 (22.3–24.8) |
Fat mass (kg)a | 22.6 (20.6–24.5) | 22.1 (20.1–24.1) | 23.6 (20.8–26.4) | 22.5 (19.3–25.7) |
Fat (%)a | 34.1 (32.1–36.0) | 33.4 (31.5–35.2) | 34.9 (32.3–37.4) | 33.3 (30.4–36.2) |
Android fat (%)a | 35.8 (31.7–39.8) | 35.2 (31.0–39.4) | 35.9 (30.7–41.1) | 34.2 (28.4–40.0) |
Gynoid fat (%)a | 40.0 (38.0–41.9) | 38.8 (37.1–40.6) | 41.0 (38.9–43.1) | 38.4 (36.0–40.8) |
Android/gynoid ratio | 0.89 (0.80–0.99) | 0.91 (0.80–1.01) | 0.86 (0.76–0.96) | 0.87 (0.76–0.99) |
Maximal oxygen uptake (ml O2/min)a | 2085 (1952–2218) | 2308 (2174–2442) | 2018 (1887–2148) | 2241 (2108–2374) |
FSH (IU/L)b | 12.6 (7.2–18.1) | 12.8 (7.7–18.0) | 96.0 (82.8–109.3) | 90.7 (79.7–101.7) |
Estradiol/SHBG indexb | 6.5 (4.3–9.8) | 7.0 (4.6–10.6) | 1.4 (1.1–1.7) | 1.3 (1.1–1.6) |
Bioavailable testosterone (ng/dL)b | 5.3 (4.3–6.5) | 4.9 (4.0–6.1) | 4.0 (3.0–4.9) | 3.7 (3.0–4.6) |
Data are presented as mean (95% confidence limits). Group differences and effect of the intervention were assessed by a two-way ANOVA.
Change from baseline to 3 months: (p ≤ 0.05).
Difference between groups (p ≤ 0.05). BMI, Body Mass Index; FSH, Follicle stimulating hormone; SHBG, sex hormone binding globulin.